Hosted by Informa Pharma Intelligence, this panel discussion will provide key inputs to consider when choosing between a make vs. buy, to scale-up manufacturing internally or look to an external supplier like a CDMO. We will hear from industry experts on the state of the advanced therapy industry, the investment that is pouring into advanced therapies, why manufacturing is such a critical component, various approaches to the build or buy decision and advantages and challenges of the decision.
Francis Pang, Ramesh Arjunji, and Jeremy Schafer will share lessons learned from prior launches and discuss how cell and gene therapies are reshaping commercializing strategies. Some of the topics explored will be tensions between cost-effectiveness and affordability, evidence generation strategies and development, and communication to payers and health technology appraisal organizations.
Join MassBio and Precision for a one-of-a-kind panel discussion with a unique group of experts in cell and gene therapy studies. These pioneers have been involved in multiple programs that led to FDA-approved cell and gene therapies. They will share lessons learned from experience, giving you actionable insights on every stage of a trial—from the lab, to studies, to logistics and biomanufacturing.